IMVT

Immunovant Inc · NASDAQ

Sector Health Technology
Industry Biotechnology
Website immunovant.com
Employees(FY) 164
ISIN US45258J1025

Performance

-10.59%

-11.2%

-16.04%

-14.76%

-37.88%

YTD

-22.57%

Profile

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.

Advanced Technical Analysis

Technical Analysis of IMVT 2024-11-20

The stock indicators reflect a bearish sentiment overall, with a Moving Average Score of 10 indicating strong downward momentum, an Oscillators Score of 46 suggesting a neutral stance, and a Technical Score of 28 reinforcing the bearish outlook. This combination points to potential challenges for the stock in gaining upward traction in the near ...

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of IMVT

Stock Rank

Recent News & Updates

2024-11-13 03:05
Q2 2024 Roivant Sciences Ltd Earnings Call(Thomson Reuters StreetEvents)
2024-11-08 10:38
Immunovant's Q2 Loss Wider Than Expected, Pipeline in Focus(Zacks)
2024-11-07 08:56
Immunovant Fiscal Q2 Net Loss Widens(MT Newswires)
2024-11-07 06:30
Immunovant Provides Development Updates and Reports Financial Results for the Quarter Ended September 30, 2024(GlobeNewswire)
2024-11-06 17:30
Immunovant Provides Development Updates and Reports Financial Results for the Quarter Ended September 30, 2024(Globenewswire)
2024-10-29 06:30
Immunovant Announces Oral Presentation of Late Breaking Abstract for Phase 2 Graves’ Disease Clinical Data at the 2024 American Thyroid Association (ATA) Annual Meeting(GlobeNewswire)
2024-10-28 18:30
Immunovant Announces Oral Presentation of Late Breaking Abstract for Phase 2 Graves' Disease Clinical Data at the 2024 American Thyroid Association (ATA) Annual Meeting(Globenewswire)
2024-10-18 16:37
Immunovant Insider Sold Shares Worth $261,845, According to a Recent SEC Filing(MT Newswires)
2024-10-09 08:14
Oppenheimer Adjusts Immunovant Price Target to $53 From $47, Maintains Outperform Rating(MT Newswires)
2024-10-01 09:58
Is Immunovant, Inc. (IMVT) the Worst Performing Stock to Buy on the Dip?(Insider Monkey)
2024-09-30 11:12
Is Roivant Sciences Ltd. (NASDAQ:ROIV) The Best NASDAQ Stock Under $50 To Buy?(Insider Monkey)
2024-09-09 14:23
Citigroup Raises Immunovant's Price Target to $60 From $51, Buy Rating Maintained(MT Newswires)
2024-09-09 12:54
What's Going In With Vivek Ramaswamy-Founded Roivant Sciences Stock On Monday?(Benzinga)
2024-09-09 09:13
Immunovant touts positive Phase II batoclimab data as IMVT-1402 also progresses(Pharmaceutical Technology)
2024-09-09 08:35
IMVT Stock Up on Upbeat Data From Graves' Disease Study of Batoclimab(Zacks)
2024-09-09 07:09
Immunovant's Graves' Disease Drug Shows Improved Efficacy at Higher Doses(MT Newswires)
2024-09-09 07:00
Roivant Provides Update on Graves’ Disease Development Program(GlobeNewswire)
2024-09-09 03:55
Immunovant Provides Update on Graves’ Disease Development Program(GlobeNewswire)
2024-09-08 19:32
Immunovant touts positive Phase II batoclimab data as IMVT-1402 also progresses(Yahoo Finance)
2024-09-08 19:00
Roivant Provides Update on Graves' Disease Development Program(Globenewswire)
2024-09-08 15:55
Immunovant Provides Update on Graves' Disease Development Program(Globenewswire)
2024-09-05 11:31
Why Is Immunovant (IMVT) Up 13.8% Since Last Earnings Report?(Zacks)
2024-09-05 06:30
Immunovant to Host Graves’ Disease Program Update on September 9, 2024(GlobeNewswire)
2024-09-04 18:30
Immunovant to Host Graves' Disease Program Update on September 9, 2024(Globenewswire)
2024-09-02 06:48
Are Investors Undervaluing Immunovant, Inc. (NASDAQ:IMVT) By 46%?(Simply Wall St.)
2024-08-23 16:13
Immunovant Insider Sold Shares Worth $480,052, According to a Recent SEC Filing(MT Newswires)
2024-08-13 09:59
UBS Trims Price Target on Immunovant to $41 From $42, Maintains Buy Rating(MT Newswires)
2024-08-09 00:20
Q1 2025 Roivant Sciences Ltd Earnings Call(Thomson Reuters StreetEvents)
2024-08-06 16:05
Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended June 30, 2024(GlobeNewswire)
2024-07-23 09:37
We Think Immunovant (NASDAQ:IMVT) Can Afford To Drive Business Growth(Simply Wall St.)

Page 1 of 7

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.